Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study

In Vivo

Volumn 21, Issue 6, 2007, Pages 1085-1092

  Fiorentini, Giammaria ^a   Aliberti, Camillo ^b   Turrisi, Gina ^a   Del Conte, Alessandro ^a   Rossi, Susanna ^a   Benea, Giorgio ^b   Giovanis, Petros ^c  

^a San Giuseppe Hospital   (Italy)

^b Delta Hospital   (Italy)

^c Belluno City Hospital   (Italy)

Author keywords

Colorectal cancer; DC beads; Hepatic angiography; Intraarterial chemotherapy; Irinotecan; Liver metastasis

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CEFAZOLIN; CONTRAST MEDIUM; DEXAMETHASONE; FLUOROURACIL; IRINOTECAN; MORPHINE; OXALIPLATIN; RANITIDINE; TROPISETRON;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ACUTE PANCREATITIS; ARTICLE; BONE MARROW TOXICITY; CANCER GRADING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; FEVER; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDRATION; INFECTION PREVENTION; INOPERABLE CANCER; KIDNEY FAILURE; LENGTH OF STAY; LIVER METASTASIS; LIVER WEIGHT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; TREATMENT RESPONSE;

EID: 37349032977     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Vogl TJ, Zangos S, Eichler K, Yakoub D and Nabil M: Colorectal liver metastases: regional chemotherapy via transarterial. chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 17: 1025-1034, 2007.
2. Chong G and Cunningham D: Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol 23: 9063-9066, 2005.
3. Cohen AD and Kemeny NE: An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8: 553-566, 2003.
4. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F and Bismuth F: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8: 347-353, 2001.
5. Adam R: Chemotherapy and surgery: New prospectives on the treatment of unresectable liver metastases. Ann Oncol 14(Suppl 2): ii13-ii16, 2003.
6. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ and Donohue JH: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J Clin Oncol 23: 9243-9249, 2005.
7. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
9. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N and Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
11. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwicbel J and Kaplan RS: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24: 3354-3360, 2006.
12. Cunningham E, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
13. Saltz LB, Lenz H, Hochster H, Wadler S, Hoff P, Kemeny N, Hollywood E, Gonen M, Wetherbee S and Chen H: Randomized phase II trial of cetuximab/ bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 23(Suppl): Abstract 3508, 2005.
14. Schrag D: The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 351: 317-319, 2004.
15. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH and Kylstra JW: Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 12: 318-326, 2006.
16. Berber E, Pelley R and Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 23: 1358-1364, 2005.
17. Aliberti C, Tilli M, Benea G and Fiorentini G: Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: Preliminary results. Anticancer Res 26: 3793-3796, 2006.
18. Morise Z, Sugioka A, Kato R, Fujita J, Hoshimoto S and Kato T: Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. J Gastrointest Surg 10(2): 249-258, 2006.
19. Fiorentini G, Rossi S, Bonechi F, Vaira M, De Simone M, Dentico P, Bernardeschi P, Cantore M and Guadagni S: Intraarterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II Study. J Chemotherapy 16(3): 293-297, 2004.
20. Muller H, Nakchbandi V, Chatzisavvidis I and von Voigt C: Repetitive chemoembolization with meplhalan plus intraarterial immuno-chemotherapy with 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Hepatogastroenterology 50: 1919-1926, 2003.
21. Popov I, Lavrnic S, Jelic S, Jezdic S and Jasovic A: Chemoembolization for liver metastases from colorectal carcinoma: risk or benefit. Neoplasma 49: 43-48, 2002.
22. Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A and Schmoll HJ: A new chemoembolization protocol in refractory liver metastasis of colorectal cancer: a feasibility study. Onkologie 25: 158-164, 2002.
23. Hunt TM, Flowerdrew AD, Birch SJ, Williams JD, Mullee MA and Taylor I: Prospective randomized controlled trial of hepatic arterial embolization or infusione chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 77: 779-782, 1990.
24. Martinelli DJ, Wadler S, Bakal CW, Cynamon J, Rozenblit A, Haynes H, Kaleya R and Wiernik PH: Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 74: 1706-1712, 1994.
25. Salman HS, Cynamon J, Jagust M, Bakal C, Rozenblit A, Kaleya R, Negassa A and Wadler S: Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2: 173-179, 2002.
26. You Y-T, Changchien C-R, Huang J-S and Ng KK: Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. In J Colorectal Dis 21: 33-37, 2006.
27. Fiorentini G, Aliberti C, Tilli M and Benea G: Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal cancer (CRC) using irinotecan-eluting beads. Gastrointestinal Cancers Symposium, ASCO/Proceedings, Abstract 356: 261, 2007.
28. Llovet JM, Real MI, MontanaX, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J and Bruix J: Arterial embolization or chemoembolization versus systemic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002.
29. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST and Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
30. Fiorentini G, Lucchi SR, Giovanis P, Cantore M, Guadagni S and Papiani G: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: results of a phase I clinical study. Tumori 87(6): 388-390, 2001.
31. Fiorentini G, Rossi S, Dentico P, Bernardeschi P, Calcinai A, Bonechi F, Cantore M, Guadagni S and De Simone M: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 89(4): 382-384, 2003.
32. van Riel JM, van Groeningen CJ, Kedde MA, Gall H, Leisink JM, Gruia G, Pinedo HM, van der Vijgh WJ and Giaccone G: Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 8: 405-412, 2002.
33. Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, Leppard SW, Wolfenden LC, Palmer RR and Stratford PW: DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17: 335-342, 2006.
34. Taylor RR, Tang Y, Gonzalez MV, Stratford PW and Lewis AL: Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30: 7-14, 2007.
35. Tassinari D. Surrogate end points of quality of life assessment: have we really found what we are looking for? Health Quality Life Outcomes 24(1): 71-77, 2003.
36. Vignaroli E, Pace EA, Willey J, Palmer JL, Zhang T and Bruera E: The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J Palliat Med 9(2): 296-303, 2006.